Search

Displaying results 8651 - 8660 of 10000 in total
  1. Drug

    Streptococcus pneumoniae type 24F capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB19350
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … _ serotype 24F individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of _Corynebacterium diphtheriae_ strain C7 (β197).

  2. Drug

    Streptococcus pneumoniae type 31 capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB19351
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … _ serotype 31 individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of _Corynebacterium diphtheriae_ strain C7 (β197).

  3. Drug

    Streptococcus pneumoniae type 35B capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB19352
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … _ serotype 35B individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of _Corynebacterium diphtheriae_ strain C7 (β197).

  4. Drug

    Streptococcus pneumoniae type 12F capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB16716
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … * serotype 12F individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of *Corynebacterium diphtheriae* strain C7 (β197).

  5. Drug

    Tulrampator

    go.drugbank.com/drugs/DB16344
    Investigational

    Tulrampator is under investigation in clinical trial NCT02626572 (Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive

  6. Drug

    Ichorcumab

    go.drugbank.com/drugs/DB18930
    Investigational

    Ichorcumab is under investigation in clinical trial NCT03251482 (A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee

  7. Drug

    GO-203-2C

    go.drugbank.com/drugs/DB15008
    Investigational

    GO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia).

  8. Drug

    Fulacimstat

    go.drugbank.com/drugs/DB15085
    Investigational

    Fulacimstat is under investigation in clinical trial NCT02452515 (A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With

  9. Drug

    Remtolumab

    go.drugbank.com/drugs/DB15128
    Investigational

    Remtolumab is under investigation in clinical trial NCT02433340 (Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12

  10. Drug

    ZR202-CoV

    go.drugbank.com/drugs/DB27995
    Investigational

    ZR202-CoV is a biologic drug. ZR202-CoV is under investigation in clinical trial NCT05490108 (Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults.).